Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1192P - Optimizing lung cancer screening: Independent verification of an AI/ML computer-aided detection and characterization software as medical device
Presenter: Sylvain Bodard
Session: Poster session 09
1194P - Development of a novel artificial intelligence (AI) algorithm to detect pulmonary nodules on chest radiography
Presenter: Mitsunori Higuchi
Session: Poster session 09
1195P - Whole-body magnetic resonance imaging (WB-MRI) screening in Li Fraumeni syndrome for early cancer diagnosis: The SIGNIFIED project
Presenter: Elena Cojocaru
Session: Poster session 09
1196P - Organoid growth-based oncological sensitivity test (OncoSensi) for predicting adjuvant therapy outcomes in ovarian cancer patients
Presenter: Dong Woo Lee
Session: Poster session 09
1197P - Ex vivo basket study reports patient-specific sensitivity to carboplatin versus cisplatin in lung, ovarian and bladder cancer
Presenter: Debbie Robbrecht
Session: Poster session 09
1198P - Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Presenter: Pontis Julien
Session: Poster session 09